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Introduction
Cholangiocarcinoma (CCA) or bile duct cancer is a 
malignant cancer of the biliary duct system that originates 
in the liver and extrahepatic bile ducts which terminate 
at the ampulla of Vater (Mosconi et al., 2009). Recent 
statistics showed an increasing worldwide incidence and 
mortality rate of 3% of all gastrointestinal cancers, and 
is the second usual primary hepatic tumor (Rizvi and 
Gores, 2013). Most CCA cases occur in populations aged 
over 60 years with yearly incidence of approximately 
5.5 and 7.3 cases per 100,000 populations in Japan and 
Israel, and 1-2 cases per 100,000 populations in the UK 
and the USA, respectively (Singh and Facciuto, 2012). 
The highest incidence rate is reported in the northeastern 
region of Thailand particularly in Khon Kaen province, 
with age standardized rate of 89.2 per 100,000 in men, 
and 37.4 per 100,000 in women (range: 93.8 to 317.6 per 
100,000) (Sriamporn et al., 2004). The major cause of 
CCA in Thailand is consumption of improperly cooked 
and fermented fresh water cyprinoid fish called ‘Pla-ra’, 
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Abstract
 Opisthorchis viverrini (OV)-induced cholangiocarcinoma (CCA) is an important cancer in the Great Mekong 
region, particularly in Thailand. Limitations of treatment options and the lack of an effective diagnostic tool 
for early detection of CCA are major concerns for the control of this type of cancer. The aim of the study was to 
investigate anti-CCA activity of the ethanolic extract of Atractylodes lancea (Thunb.) DC., and the applicability 
of positron emission tomography-computed tomography (PET-CT) as a tool for detection and monitoring the 
progression of CCA in Opisthorchis viverrini (OV)/dimethylnitrosamine (DMN)-induced CCA hamsters. Male 
Syrian hamsters were used for toxicity tests and anti-CCA activity evaluation. Development of CCA was induced 
by initial feeding of 50 metacercariae of OV, followed by drinking water containing 12.5 ppm of DMN in hamsters. 
The ethanolic extract of A. lancea (Thunb.) DC. was administered orally for 30 days. PET-CT was performed 
every 4 weeks after initiation of CCA using 18F-fluorodeoxyglucose (18F-FDG). Results from the present study 
suggest that the ethanolic extract of A. lancea (Thunb.) DC. rhizome exhibited promising anti-CCA activity 
and safety profile in the OV/DMN-induced hamster model. To successfully apply PET-CT as a tool for early 
detection of tumor development and progression, modification of radiolabeling approach is required to improve 
its specificity for CCA cells. 
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‘Pla-som’, or ‘Koi-pla’ which contains the liver fluke 
Opisthorchis viverrini (OV) and the pre-carcinogen 
nitrosamine (Sithithaworn et al., 2012). The risk factors 
in western countries are infection with hepatic C virus and 
primary sclerosing cholangitis (PSC) (Khan et al., 2008).
The dried rhizomes of Atractylodes lancea (Thunb.) 
DC. (Khod-Kha-Mao or Cang Zhu), family Compositae, 
is a common medicinal plants used in traditional Chinese 
medicine and Japanese campo, as well as in Thai 
traditional medicine in drug formulation for treatment of 
fever, colds, flu, sore throat, rheumatic diseases, digestive 
disorders, night blindness, and influenza (Chayamarit, 
1995; Xio, 2002). The major constituents are atractylodin, 
β-eudesmol, atractylon, and hinesol (Ouyang et al., 2007). 
β-eudesmol has been reported to be the main and active 
component of A. lancea (Thunb.) DC (Ouyang et al., 
2007; Chen et al., 2007). These compounds including 
the rhizome extract have been shown to possess several 
pharmacological activities including anti-inflammatory 
(Resch et al., 2001), anti-angiogenic (Tsuneki et al., 
2005), antimicrobial (Wang et al., 2009; Chen et al., 
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2012), antihypertensive (Plengsuriyakarn et al., 2012), 
anti-ulcer and inhibitory activities on gastric secretion 
(Kubo et al., 1983; Nogami et al., 1986), as well as 
activity on nervous system (Nojima et al., 1992). Results 
of our previous studies demonstrated promising anti-CCA 
activity of the ethanolic extract of A. lancea (Thunb.) 
DC. (rhizome) in various in vitro and in vivo models. 
The cytotoxic activity against the CCA cell line CL-6 
was shown with IC50 (concentration that inhibits cell 
growth by 50%) of 24.09 µg/ml. In addition, the extract 
also produced inhibitory activity on tube formation, cell 
invasion (Mahavorasirikul et al., 2010; Plengsuriyakarn 
et al., 2012), and anti-CCA activity in CCA-xenografted 
nude mice at all dose levels (1,000, 3,000, and 5,000 mg/
kg body weight) (Plengsuriyakarn et al., 2012).
Besides the limitation of effective chemotherapeutics, 
one of the major problems for the treatment and control 
of CCA is the lack of effective diagnostic tool for early 
detection of the cancer. The imaging technology Positron 
Emission Tomography with Computed Tomography (PET-
CT) with 18F-FDG has been shown to be a promising 
approach for screening of various types of human cancer, 
i.e., lung cancer (Lardinois et al., 2003), colorectal 
cancer (Cohade et al., 2003), and lymphoma (Tatsumi 
et al., 2005), including regional and distal metastases of 
CCA (Breitenstein et al., 2008; Sacks et al., 2011). The 
aim of the present study was to investigate anti-CCA 
activity of the ethanolic extract of Atractylodes lancea 
(Thunb.) DC. In addition, the applicability of Positron 
Emission Tomography-Computed Tomography (PET-CT) 
imaging system as a tool for detection and monitoring the 
progression of CCA was also investigated in Opisthorchis 




5-fluorouracil (5-FU), dimethylnitrosamine 
(DMN), Tween-80, and ethanol were purchased from 
Wako Pure Chemical Industries, Ltd. (Osaka, JPN). 
18F-fluorodeoxyglucose (18F-FDG) was purchased from 
Japan Radioisotope Association (JRIA).
Animals
Male and female Syrian hamsters (6 weeks of age, 
weighting 100-120 g) were purchased from Japan SLC 
Inc. (Japan). They were housed under standard conditions 
and fed with a stock diet and water ad libitum. Approval 
of the study protocol was obtained from the Ethics 
Committee of Nagasaki University, Japan (Approval 
number 1303011046) and Thammasat University, 
Thailand (Approval number 013/2556). 
Preparation of plant extract
The rhizomes of A. lancea (Thunb.) DC. (voucher 
number SKP 051011201) were rinsed thoroughly with 
tap water and cut into small pieces, oven-dried at 50°C 
until stability of the dry weight was observed, and then 
ground into powder with an electric-grinder (NBMT 21; 
Chennai, India). Extraction was carried out by macerating 
the powdered A. lancea (Thunb.) DC. (100 g) in a 
stopper flask containing 500 ml of 95% ethanol at room 
temperature (25-30°C) for 7 days. The extracted solvent 
was separated and filtered through Whatman no. 1 filter 
paper (GE Healthcare, Maidstone, UK). After filtration, 
the extract was evaporated under reduced pressure by 
rotary evaporation. The dried powder were weighed and 
stored at -20°C until use. The extract was standardized 
using high-performance liquid chromatography (HPLC) 
to determine the amount of β-eudesmol. Chromatographic 
separation condition used was as follow: Thermo Hypersil 
Gold C18 column (Thermo Scientific, Rockford, IL, 
USA), and mobile phase consisting of a mixture of water 
and acetonitrile with isocratic elution of 40:60 (v:v) at 
the flow rate of 1 ml/min and run time of 30 min. The 
wavelength was set at 203 nm.
In vivo model for evaluation of toxicity
Acute and repeated doses toxicity tests were performed 
in accordance with the OECD guideline for testing of the 
chemicals (OECD 2004; OECD 2008). For acute toxicity, 
healthy hamsters (5 males and 5 females) were fed (via 
intragastric gavage) with a single dose of 5,000 mg/kg 
body weight of A. lancea (Thunb.) DC. (resuspended in 
a mixture of distilled water and tween-80 at the ratio of 
4:1, v:v). For repeated doses toxicity, three dose levels 
of A. lancea (Thunb.) DC., i.e., 1,000, 3,000, and 5,000 
mg/kg body weight were administered to the healthy 
hamsters (5 males and 5 females for each group) daily for 
28 days. The control hamsters were fed with the mixture of 
distilled water and Tween-80. Animals were observed for 
awareness, status of mood, motor activity, CNS excitation, 
posture, muscle tone, reflexes, and autonomic signs during 
the first 30 minutes, periodically during the first 24 hours, 
and then daily for 14 days (acute toxicity) or 28 days 
(repeated doses toxicity). At the end of the observational 
period, all animals were sacrificed under ether anesthesia 
and vital organs were removed from all animals.
In vivo model for evaluation of activity against 
cholangiocarcinoma 
The metacercariae of OV were collected as the 
naturally infected cyprinoids fish captured from an 
endemic area of Khon Kaen, northeast Thailand. The 
parasite species were confirmed under light microscope 
and the metacercariae were minced and digested with 
pepsin-hydrichloric acid, then filtrated and washed with 
normal saline. Development of CCA was induced by 
initial feeding of male hamsters (by gastric gavage) with 
50 metacercariae of OV, followed four weeks later by 
drinking water containing 12.5 ppm of DMN for eight 
weeks (Thamavit et al., 1987). The first five groups were 
treated as OV-infected groups and the last group served 
as normal control of healthy hamsters. The occurrence 
and development of CCA was detected and confirmed 
by ultrasonography throughout the investigation period 
and divided into six groups (6 males for each group) as 
follows:
Group 1 (5-FU treated control): CCA hamsters treated 
with 5-FU (40 μg/ml) daily for 14 doses.
Group 2 (untreated control): CCA hamsters treated 
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with vehicle (a mixture of distilled water and tween-80) 
daily for 30 days.
Group 3 (high dose): CCA hamsters treated with 5000 
mg/kg body weight of A. lancea (Thunb.) DC. daily for 
30 days.
Group 4 (medium dose): CCA hamsters treated with 
3000 mg/kg body weight of A. lancea (Thunb.) DC. daily 
for 30 days.
Group 5 (low dose): CCA hamsters treated with 1000 
mg/kg body weight of A. lancea (Thunb.) DC. daily for 
30 days.
Group 6 (normal control): Healthy hamsters treated 
with vehicle (a mixture of distilled water and tween-80) 
daily for 30 days.
Body weight, food and water consumption were 
recorded daily for 30 days. Survival time and survival 
rate were the primary endpoint parameters for evaluation 
of the anticancer activity of the crude ethanolic extract of 
A. lancea (Thunb.) DC.
PET-CT for  assessment  o f  ac t i v i t y  aga ins t 
cholangiocarcinoma 
PET-CT imaging was applied for detection and 
monitoring the progression of CCA using a small animal 
PET scanner, FLEXTM TriumphTM (Gamma Medica-Ideas, 
CA, USA). Before experiment, all hamsters were fasted 
overnight and injected with 10-15 MBq of 18F-FDG 
via the cephalic vein. After a 30 minutes period for the 
accumulation of 18F-FDG inside the internal organs, 
animals were anesthetized with isoflurane and started 
perform Triumph XO CT system and following by 
acquisition of PET image using LabPET system for 1h. 
The images were reconstructed by the ordered subsets 
expectation maximization algorithm and analyzed using 
VIVIDTM program (Gamma Medica-Ideas, CA, USA). 
The standardized UV uptake (SUV) was calculated using 
the formula:
SUV = Tumor FDG concentration (Bq/ml)
Injected dose (Bq)/Body weight (g)
Autopsy and histopathology
All organs were removed at autopsy and observed 
macroscopically. Samples were fixed with 10% buffer 
formalin solution. Specimens were washed in phosphate 
buffer three times, dehydrated in an ascending series of 
ethanol for 15 min each, embedded in paraffin, followed 
by sectioning and staining with hematoxylin and eosin.
 
Statistical analysis
All quantitative variables are presented as medians 
with 95% CI (confidence interval). Comparison of the 
quantitative variables between unrelated groups was 
performed using ANOVA and Mann-Whitney U test. For 
the quantitative two related groups, Wilcoxon Signed Rank 
test was applied. Statistical significance level was set at 
α= 0.05 for all tests.
Results 
Standardization of A. lancea (Thunb.) DC. extract
The yield of A. lancea (Thunb.) DC. following 
extraction of the dried rhizomes with 95% ethanolic was 
16.89%. The amount of β-eudesmol analyzed by HPLC 
was 6.73%. The chromatogram of separation was shown 
in Figure. 1.
Toxicity test
No animal died during the observation period. Only 
mild signs of acute toxicity occurred in all hamsters 
receiving all dose levels of A. lancea (Thunb.) DC. as well 
as the control vehicle. These included stomach irritation, 
and general CNS depressant signs (reduced alertness 
and locomotion, and diminished response to touch and 
balance) was observed within 1 hour after feeding with 
highest dose (5,000 mg/kg) of the A. lancea (Thunb.) DC. 
No histopathological abnormality was observed in any 
vital organ at autopsy.
Figure 1. Standardization of the Ethanolic Extract 
of A. lancea (Thunb.) DC. Using High-Performance 
Liquid Chromatography
Figure 2. Change in the Body Weights (Median with 
95% CI) of Hamsters in the 6 Group
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Anticholangiocarcinoma activity
The average body weights of the OV/DMN-induced 
CCA hamsters in groups 1-5 were significantly reduced 
after DMN withdrawal compared with normal control 
hamsters (Figure 2). The morphological examination 
of OV/DMN-induced hamsters (group 1-5) but normal 
hamsters (group 6) showed identical features of bile 
duct epithelium and liver parenchymal cells such as the 
enlargement of bile duct, pus and shape change of the 
liver (Figure 3). Histopathological examination of all 
OV/DMN-induced CCA hamsters (group 1-5), but not 
normal control group (group 6), confirmed the occurrence 
of CCA with proliferation and cystic formation of bile 
duct and infiltration of inflammatory cells (lymphocytes, 
plasma cells, and macrophages) around portal areas. For 
the untreated control group, the OV parasite was found 
in bile duct with severe degeneration and necrosis of 
hepatocytes (Figure 3). The histopathological lesion of 
the bile ducts was markedly less pronuced in A. lancea 
(Thunb.) DC. treated hamsters, with only mild diffuse 
proliferation, cystic formation and fibrosis of bile ducts 
(Figure 3). No remarkable lesion was found in normal 
control group (group 6).
The median survival rate and survival time were 
significantly prolonged (about 2 times) in animals treated 
with the extract at all dose levels (group 3-5) compared 
with 5-FU treated (group 1), and untreated control (group 
2) groups during the 4-6 months observation period 
(p<0.01, Table 1). At week 36, all animals except those 
treated with the extract at the highest dose level (5,000 
mg/kg: group 3); only one animal died (80% survival 
rate). The untreated control animals started to die as early 
as 14 weeks. 
PET-CT imaging
PET-CT imaging system was used for first time 
evaluation and detection of CCA development in OV/
DMN-induced CCA hamster with 18F-FDG. PET images 
were fused with CT images to improve interpretation 
accuracy to compare between CCA-bearing hamster and 
normal group in Figure 4. Coronal views of PET-CT 
studies showed 18F-FDG accumulation inside the livers, 
and kidneys to be similar in both the CCA-bearing and 
control hamsters. PET-CT images of cancerous hamster 
exhibited 18F-FDG uptake throughout the liver at 8 to 
Table 1. Survival Time (Days: Median with 95% CI) of OV/DMN-induced CCA-hamsters following Treatment 
with A. Lancea (Thunb.) DC. in Comparison with Untreated Control 
Control hamsters  Treated hamsters
Untreated a  5-FU-treated b High dose Medium dose Low dose
(Group 1) (Group 2) (Group 3) (Group 4) (Group 5)
15.5 (14.3-16.7) 20.7 (19.0-22.4) 37.3 (36.1-38.5) 34.2 (32.8-35.6) 27.9 (26.1-29.7)
aStatistically significant difference with Group 3 (p<0.01), Group 4 (p<0.01), and Group 5 (p<0.01); bStatistically significant difference with Group 
3 (p<0.01), Group 4 (p<0.01), and Group 5 (p<0.01)
Figure 3. Morphology and Histopathology of Livers 
in OV/DMN-induced CCA-Hamsters Following 
Treatment with A. lancea (Thunb.) DC. in Comparison 
with Untreated Control, and 5-FU (Reference Control)
Figure 5. Tumor 18F-FDG Uptake Presented as 
Percentage (Median with 95% CI) of SUV Baseline 
for Cancerous and Normal Hamsters
Figure 4. Representative PET-CT Images of CCA in 
OV/DMN-Induced Hamster Model
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16 weeks after infection with OV. The median (95% CI) 
tumor 18F-FDG uptake (percentage of baseline) in CCA-
baring and normal control hamsters at week 4, 8, 12, and 
16 after OV-infection were comparable [90 (86.7-93.3) vs 
100 (97.7-102.3), 130 (119.4-140.6) vs 140 (131.7-148.3), 
170 (156.5-183.5) vs 175 (162.4-187.6), and 200 (184.2-
215.8) vs 205 (188.8-221.2) at week 4, 8, 12, and 16 after 
OV-infection, respectively] (Figure 5). 
Discussion
The ethanolic extract of A. lancea (Thunb.) DC. was 
shown to exhibit a promising anti-CCA activity and safety 
profile in OV/DMN-induced CCA hamster model. Its 
anti-CCA activity, particularly at the highest dose level of 
5,000 mg/kg body weight, was clearly demonstrated with 
a marked inhibition of tumor growth and prolongation of 
survival time compared with the standard drug 5-FU and 
untreated control. These observations confirm the previous 
reports for the potent activity of the plant extract against 
CCA in xenograft mouse model where significant reduction 
in tumor size (by 97.3%), prolongation of survival time 
(by 208.5%), and inhibition of lung metastasis (by 
95% of total lung mass) were found, compared with 
the untreated control (Plengsuriyakarn et al., 2012). Its 
anti-CCA activity together with other complementary 
pharmacological activities on gastrointestinal system and 
inflammatory process support further development of this 
medicinal plant as a promising candidate for treatment 
of CCA. In previous studies in rats, the extract was 
shown to increase the levels of gastric hormone motilin 
and gastrin, while decreasing the level of somatostatin 
and corticotrophin-releasing factor, which result in 
improving the gastric emptying condition (Nakai et al., 
2003; Zhang et al., 2008). Furthermore, it also showed 
potent anti-inflammatory activity through inhibition of 
5-lipoxygenase (5-LOX) and cyclooxygenase-1 (COX-
1) (Resch et al., 1998) as well as antimicrobial activity 
against Rhodotorula glutinis and Saprolegnia (Wang et 
al., 2009).
Several animal models were used to investigate the 
anti-CCA activities of candidate compounds or medicinal 
plant extracts. These include xenograft and orthotopic 
models, carcinogen-induced CCA model, and genetically 
engineered mouse model (Thamavit et al., 1987; O’Dell et 
al., 2012; Zhang et al., 2012). CCA-xenograft mouse model 
in conjunction with PET-CT is widely applied in research 
on targeted drug therapy in cancers. PET-CT was also 
shown to be successfully applied in thioacetamide (TAA)-
induced CCA rat model for detection and monitoring 
the progression of CCA (Laverman et al., 2007; Yeh et 
al., 2008). The present study was the first study which 
applied PET-CT as a tool (for detection and monitoring 
the progression of cancer) for investigation of anti-CCA 
activity of a candidate medicinal plant in OV/DMN-
induced CCA hamster model. The imaging approach is 
quantitative and noninvasive without sacrificing animals 
(Cherry and Gambhir, 2007). The carcinogen-induced 
CCA model by OV infection followed by induction with 
the carcinogen DMN in hamsters mimics the pathogenicity 
of human CCA. The development and progress of CCA 
following treatment could be periodically monitored 
using the radio tracer 18F-FDG throughout the observation 
period. Unfortunately the accumulation of this marker 
compound is non-specific. 18F-FDG is accumulated in 
all tissues with high glucose uptake. It is thus, intensely 
uptaken into all living cells with high metabolic rates, 
which include not only the cancer cells but also other vital 
organs especially liver and kidney cells. This problem 
has been overcome by labeling the radio tracers with 
ligands such as monoclonal antibodies that are specific 
to the target tumors. Benvacizumab labeling with 64Cu 
was successfully developed for imaging intratumoral 
vascular endothelial growth factor (VEGF) content in 
renal carcinoma xenograft mouse model (Chang et al., 
2013). The elimination half-life of the 64Cu-monoclonal 
antibody label is relatively longer (~ 12 hours) compared 
with 18F-mono clonal antibody label (~ 2 hours).
In conclusion, results from the present study support 
the potential role of A. lancea (Thunb.) DC. rhizome for 
treatment of CCA. To successfully apply PET-CT as a tool 
for early detection of tumor development and progression, 
modification of radiolabeling approach is required to 
improve its specificity to CCA cells
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